Table 3.
Cutaneous adverse events induced by targeted therapies: synthesis table.
EGFRi | c-kit inhibitors BCR–ABLi | Angiogenesis agents | FGFRi | BRAFi | MEKi | mTORi PI3Ki | HHi | JAKi | PARPi | |
---|---|---|---|---|---|---|---|---|---|---|
Papulopustular eruption | X | X | ||||||||
Exanthema (nonspecific rash) | X | X | X | |||||||
Keratinocytic proliferation Eruption Benign and malignant neoplasms |
X |
X |
X X |
X |
X |
|||||
Hand–foot skin reaction | X | X | X | |||||||
Hair changes (alopecia, trichomegaly, hirsutism, kinking) | X | X | X | |||||||
Nail changes Paronychia and pyogenic granuloma Onycholysis |
X |
X |
X |
|||||||
Xerosis/fissures | X | X | X | |||||||
Oral Mucositis Stomatitis Dysgeusia Xerostomia |
X |
X |
X |
X |
||||||
Hypopigmentation | X | X | ||||||||
Photosensitivity reaction | X | X | X | |||||||
Panniculitis | X | |||||||||
Melanocytic lesion changes | X |
BCR–ABLi = breakpoint cluster region gene–Abelson proto-oncogene inhibitors; EGFRi = epidermal growth factor receptor inhibitors; FGFRi = fibroblast growth factor receptor inhibitors; HHi = hedgehog inhibitors; JAKi = Janus kinase inhibitos; MEKi = mitogen-activated extracellular kinase inhibitors; mTORi = mammalian target of rapamycin inhibitors; PARPi = poly-ADP ribose polymerase inhibitors; PI3Ki = phosphatidylinositol-3-kinase inhibitors